CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. (Q52932186)

From Wikidata

Jump to navigation Jump to search

scientific article published in July 2006

Language	Label	Description	Also known as
English	CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.	scientific article published in July 2006

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16792770

CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16792770

phase III clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

plaque psoriasis

1 reference

based on heuristic

inferred from title

author name string

L Dubertret

1

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16792770

W Sterry

2

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16792770

J D Bos

3

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16792770

S Chimenti

4

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16792770

S Shumack

5

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16792770

C G Larsen

6

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16792770

N H Shear

7

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16792770

K A Papp

8

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16792770

CLEAR Multinational Study Group

9

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16792770

language of work or name

0 references

publication date

1 July 2006

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16792770

British Journal of Dermatology

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16792770

155

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16792770

1

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16792770

170-181

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16792770

The immunologic basis for the treatment of psoriasis with new biologic agents

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07344.X

21 January 2018

Expression of HLA-DR molecules by keratinocytes, and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07344.X

21 January 2018

The pathogenesis of psoriasis: immunological facts and speculations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07344.X

21 January 2018

T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07344.X

21 January 2018

The role of adhesion molecules, chemotactic factors, and cytokines in inflammatory and neoplastic skin disease--1990 update

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07344.X

21 January 2018

Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07344.X

21 January 2018

Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07344.X

21 January 2018

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07344.X

21 January 2018

Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07344.X

21 January 2018

Nonparametric estimation of a delay distribution based on left-censored and right-truncated data

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07344.X

21 January 2018

Identifiers

10.1111/J.1365-2133.2006.07344.X

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16792770

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/16792770

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52932186&oldid=1538379063"